191 related articles for article (PubMed ID: 34972979)
1. Cancer Imaging in Immunotherapy.
Ak M; Eleneen Y; Ayoub M; Colen RR
Adv Exp Med Biol; 2021; 1342():431-447. PubMed ID: 34972979
[TBL] [Abstract][Full Text] [Related]
2. Cancer Imaging in Immunotherapy.
Ayoub M; Eleneen Y; Colen RR
Adv Exp Med Biol; 2020; 1244():309-324. PubMed ID: 32301025
[TBL] [Abstract][Full Text] [Related]
3. Cancer Imaging in Immunotherapy.
Eleneen Y; Colen RR
Adv Exp Med Biol; 2017; 995():141-153. PubMed ID: 28321816
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy and the role of imaging.
Carter BW; Bhosale PR; Yang WT
Cancer; 2018 Jul; 124(14):2906-2922. PubMed ID: 29671876
[TBL] [Abstract][Full Text] [Related]
5. The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST.
Inno A; Lo Russo G; Salgarello M; Corrao G; Casolino R; Galli G; Modena A; Romano L; Pusceddu S; Greco FG; Garassino MC; Gori S
Tumori; 2018; 104(2):88-95. PubMed ID: 29714647
[TBL] [Abstract][Full Text] [Related]
6. Response criteria for immunotherapy and the radiologic patterns of immune-related adverse events.
Elsherif SB; Anderson M; Chaudhry AA; Kumar SP; Gopireddy DR; Lall C; Bhosale PR
Eur J Radiol; 2022 Jan; 146():110062. PubMed ID: 34890935
[TBL] [Abstract][Full Text] [Related]
7. Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment.
Lai YC; Chang WC; Chen CB; Wang CL; Lin YF; Ho MM; Cheng CY; Huang PW; Hsu CW; Lin G
Acta Radiol; 2020 Jul; 61(7):983-991. PubMed ID: 31739675
[TBL] [Abstract][Full Text] [Related]
8. [Response criteria for malignant melanoma: RECIST and irRC].
Spiro J; Maintz D; Persigehl T
Radiologe; 2015 Feb; 55(2):127-35. PubMed ID: 25637198
[TBL] [Abstract][Full Text] [Related]
9. Challenges in assessing solid tumor responses to immunotherapy.
Chai LF; Prince E; Pillarisetty VG; Katz SC
Cancer Gene Ther; 2020 Aug; 27(7-8):528-538. PubMed ID: 31822814
[TBL] [Abstract][Full Text] [Related]
10. Immune-related tumour response assessment criteria: a comprehensive review.
Somarouthu B; Lee SI; Urban T; Sadow CA; Harris GJ; Kambadakone A
Br J Radiol; 2018 Apr; 91(1084):20170457. PubMed ID: 29172675
[TBL] [Abstract][Full Text] [Related]
11. Imaging of tumour response to immunotherapy.
Dromain C; Beigelman C; Pozzessere C; Duran R; Digklia A
Eur Radiol Exp; 2020 Jan; 4(1):2. PubMed ID: 31900689
[TBL] [Abstract][Full Text] [Related]
12. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.
Tazdait M; Mezquita L; Lahmar J; Ferrara R; Bidault F; Ammari S; Balleyguier C; Planchard D; Gazzah A; Soria JC; Marabelle A; Besse B; Caramella C
Eur J Cancer; 2018 Jan; 88():38-47. PubMed ID: 29182990
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors: Assessment of the performance and the agreement of iRECIST, irRC, and irRECIST.
Yirgin IK; Dogan I; Engin G; Vatansever S; Erturk SM
J Cancer Res Ther; 2024 Jan; 20(1):156-162. PubMed ID: 38554314
[TBL] [Abstract][Full Text] [Related]
14. Tumor response assessment on imaging following immunotherapy.
Berz AM; Dromain C; Vietti-Violi N; Boughdad S; Duran R
Front Oncol; 2022; 12():982983. PubMed ID: 36387133
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of RECIST 1.1 and iRECIST for Response Evaluation in Solid Tumours].
Houdek Š; Büchler T; Kindlová E
Klin Onkol; 2017; 30(Supplementum3):32-39. PubMed ID: 29239190
[TBL] [Abstract][Full Text] [Related]
16. [Radiological response assessment of modern immunotherapy using iRECIST].
Persigehl T; Poeppel TD; Sedlaczek O
Radiologe; 2017 Oct; 57(10):826-833. PubMed ID: 28812098
[TBL] [Abstract][Full Text] [Related]
17. [Re-Analysis of Cancer Vaccine Patients with Immune-Related Clinical Response Criteria(irRC)].
Nishida K; Saito T; Urakawa S; Mori M; Kakimi K; Doki Y; Wada H
Gan To Kagaku Ryoho; 2018 Oct; 45(10):1466-1468. PubMed ID: 30382047
[TBL] [Abstract][Full Text] [Related]
18. iRECIST: how to do it.
Persigehl T; Lennartz S; Schwartz LH
Cancer Imaging; 2020 Jan; 20(1):2. PubMed ID: 31900236
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
[TBL] [Abstract][Full Text] [Related]
20. Elevated tumor markers for monitoring tumor response to immunotherapy.
Yang Y; Jiang X; Liu Y; Huang H; Xiong Y; Xiao H; Gong K; Li X; Kuang X; Yang X
EClinicalMedicine; 2022 Apr; 46():101381. PubMed ID: 35434583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
